Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer
Kairos Pharma evaluates ENV-105 with apalutamide in a Phase 2 trial targeting drug-resistant metastatic prostate cancer patients.
Kairos Pharma is testing a new drug combo to help patients whose cancer stopped responding to current treatments. This kind of research tells you the company is working on real problems, so watch how the trial results come out.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.